Inflammatory Bowel Disease: Complexity and Variability Need Integration.
作者信息
Fiocchi Claudio
机构信息
Department of Pathobiology, Lerner Research Institute, Cleveland, OH, United States.
Department of Gastroenterology and Hepatology, Digestive Disease and Surgery Institute, Cleveland Clinic, Cleveland, OH, United States.
出版信息
Front Med (Lausanne). 2018 Mar 21;5:75. doi: 10.3389/fmed.2018.00075. eCollection 2018.
Abstract
摘要
相似文献
1
Inflammatory Bowel Disease: Complexity and Variability Need Integration.炎症性肠病：复杂性与变异性需整合
Front Med (Lausanne). 2018 Mar 21;5:75. doi: 10.3389/fmed.2018.00075. eCollection 2018.
2
Contribution of genes of the major histocompatibility complex to susceptibility and disease phenotype in inflammatory bowel disease.主要组织相容性复合体基因在炎症性肠病易感性及疾病表型中的作用
Lancet. 1996 May 4;347(9010):1212-7. doi: 10.1016/s0140-6736(96)90734-5.
3
4
Appropriateness of immunosuppressive drugs in inflammatory bowel diseases assessed by RAND method: Italian Group for IBD (IG-IBD) position statement.通过RAND方法评估炎症性肠病中免疫抑制药物的适用性：意大利炎症性肠病研究小组（IG-IBD）立场声明
Dig Liver Dis. 2005 Jun;37(6):407-17. doi: 10.1016/j.dld.2004.12.013.
5
Identification of a prodromal period in Crohn's disease but not ulcerative colitis.克罗恩病前驱期的识别，但溃疡性结肠炎无此情况。
Am J Gastroenterol. 2000 Dec;95(12):3458-62. doi: 10.1111/j.1572-0241.2000.03361.x.
6
7
8
Familial occurrence and inheritance studies in inflammatory bowel disease.炎症性肠病的家族发病情况及遗传研究。
Neth J Med. 1996 Feb;48(2):53-6. doi: 10.1016/0300-2977(95)00093-3.
9
Diagnostic problems and advances in inflammatory bowel disease.炎症性肠病的诊断问题与进展
Mod Pathol. 2003 Apr;16(4):347-58. doi: 10.1097/01.MP.0000064746.82024.D1.
10
Cholelithiasis in inflammatory bowel disease. A case-control study.炎症性肠病中的胆石症。一项病例对照研究。
Dis Colon Rectum. 1990 Sep;33(9):791-4. doi: 10.1007/BF02052328.
引用本文的文献
1
Properdin, transcortin and HGFAC are novel plasma biomarkers in canine chronic inflammatory enteropathies from active disease to remission.备解素、皮质转运蛋白和HGFAC是犬慢性炎症性肠病从疾病活动期到缓解期的新型血浆生物标志物。
Sci Rep. 2025 Jul 15;15(1):25443. doi: 10.1038/s41598-025-11474-0.
2
Serum proteomic and metabolomic analyses from patients with IBD identify biological pathways associated with treatment success with anti-integrin therapy.对炎症性肠病患者的血清蛋白质组学和代谢组学分析确定了与抗整合素治疗成功相关的生物学途径。
Immunol Cell Biol. 2025 Jun 12. doi: 10.1111/imcb.70039.
3
Acceptance and Commitment Therapy for Adults Living With Inflammatory Bowel Disease and Distress: A Randomized Controlled Trial.针对患有炎症性肠病和痛苦的成年人的接纳与承诺疗法：一项随机对照试验。
Am J Gastroenterol. 2024 Aug 20. doi: 10.14309/ajg.0000000000003032.
4
Epigenetic and metabolic reprogramming in inflammatory bowel diseases: diagnostic and prognostic biomarkers in colorectal cancer.炎症性肠病中的表观遗传和代谢重编程：结直肠癌的诊断和预后生物标志物
Cancer Cell Int. 2023 Nov 7;23(1):264. doi: 10.1186/s12935-023-03117-z.
5
Pro-Inflammatory Diet Is Correlated with High , Gut Inflammation and Clinical Relapse of Inflammatory Bowel Disease.促炎饮食与肠道炎症和炎症性肠病的临床复发有关。
Nutrients. 2023 Sep 26;15(19):4148. doi: 10.3390/nu15194148.
6
Omics and Multi-Omics in IBD: No Integration, No Breakthroughs.炎症性肠病中的组学和多组学：没有整合，就没有突破。
Int J Mol Sci. 2023 Oct 5;24(19):14912. doi: 10.3390/ijms241914912.
7
Defining the Roles of Inflammatory Bowel Disease Clinical Pharmacists in the United States: A Systematic Review and National RAND/UCLA Consensus.定义美国炎症性肠病临床药师的角色：系统评价和国家 RAND/UCLA 共识。
Inflamm Bowel Dis. 2024 Jun 3;30(6):950-959. doi: 10.1093/ibd/izad143.
8
Gut microbiome signatures of Yorkshire Terrier enteropathy during disease and remission.肠道微生物组特征分析：约克夏肠病在患病期和缓解期的表现
Sci Rep. 2023 Mar 16;13(1):4337. doi: 10.1038/s41598-023-31024-w.
9
Prescriber Perspectives on Biosimilar Adoption and Potential Role of Clinical Pharmacology: A Workshop Summary.《关于生物类似药采用的处方医生观点和临床药理学的潜在作用：研讨会总结》。
Clin Pharmacol Ther. 2023 Jan;113(1):37-49. doi: 10.1002/cpt.2765. Epub 2022 Nov 4.
10
Special Issue "Advances in Gastrointestinal and Liver Disease: From Physiological Mechanisms to Clinical Practice".特刊“胃肠与肝脏疾病进展：从生理机制到临床实践”
J Clin Med. 2022 May 16;11(10):2797. doi: 10.3390/jcm11102797.
本文引用的文献
1
Predictable response: Finding optimal drugs and doses using artificial intelligence.可预测反应：利用人工智能寻找最佳药物和剂量。
Nat Med. 2017 Nov 7;23(11):1244-1247. doi: 10.1038/nm1117-1244.
2
Lost in Thought - The Limits of the Human Mind and the Future of Medicine.陷入沉思——人类思维的局限与医学的未来
N Engl J Med. 2017 Sep 28;377(13):1209-1211. doi: 10.1056/NEJMp1705348.
3
The IBD interactome: an integrated view of aetiology, pathogenesis and therapy.IBD 相互作用组：病因学、发病机制和治疗的综合观点。
Nat Rev Gastroenterol Hepatol. 2017 Dec;14(12):739-749. doi: 10.1038/nrgastro.2017.110. Epub 2017 Aug 23.
4
Inflammatory Bowel Diseases: Review of Known Environmental Protective and Risk Factors Involved.炎症性肠病：已知环境保护和危险因素的综述。
Inflamm Bowel Dis. 2017 Sep;23(9):1499-1509. doi: 10.1097/MIB.0000000000001217.
5
Genetics of inflammatory bowel disease: beyond NOD2.炎症性肠病的遗传学：超越 NOD2。
Lancet Gastroenterol Hepatol. 2017 Mar;2(3):224-234. doi: 10.1016/S2468-1253(16)30111-X. Epub 2017 Feb 9.
6
Artificial intelligence in medicine.医学中的人工智能。
Metabolism. 2017 Apr;69S:S36-S40. doi: 10.1016/j.metabol.2017.01.011. Epub 2017 Jan 11.
7
Embracing Complexity beyond Systems Medicine: A New Approach to Chronic Immune Disorders.超越系统医学拥抱复杂性：慢性免疫疾病的新方法
Front Immunol. 2016 Dec 12;7:587. doi: 10.3389/fimmu.2016.00587. eCollection 2016.
8
The dark side of the human genome.人类基因组的阴暗面。
Nature. 2016 Oct 13;538(7624):275-277. doi: 10.1038/538275a.
9
Predicting the Future - Big Data, Machine Learning, and Clinical Medicine.预测未来——大数据、机器学习与临床医学。
N Engl J Med. 2016 Sep 29;375(13):1216-9. doi: 10.1056/NEJMp1606181.
10
Linking the Microbiota, Chronic Disease, and the Immune System.连接微生物群、慢性疾病和免疫系统。
Trends Endocrinol Metab. 2016 Dec;27(12):831-843. doi: 10.1016/j.tem.2016.08.003. Epub 2016 Sep 10.
Zotero 插件